175 related articles for article (PubMed ID: 33361273)
1. Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.
Gmeiner WH; Dominijanni A; Haber AO; Ghiraldeli LP; Caudell DL; D'Agostino R; Pasche BC; Smith TL; Deng Z; Kiren S; Mani C; Palle K; Brody JR
Mol Cancer Ther; 2021 Mar; 20(3):553-563. PubMed ID: 33361273
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model.
Okechukwu CC; Ma X; Sah N; Mani C; Palle K; Gmeiner WH
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611037
[TBL] [Abstract][Full Text] [Related]
3. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with
Haber AO; Jain A; Mani C; Nevler A; Agostini LC; Golan T; Palle K; Yeo CJ; Gmeiner WH; Brody JR
Mol Cancer Res; 2021 Apr; 19(4):565-572. PubMed ID: 33593942
[TBL] [Abstract][Full Text] [Related]
4. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects.
Gmeiner WH; Okechukwu CC
Cancer Drug Resist; 2023; 6(2):257-272. PubMed ID: 37457133
[TBL] [Abstract][Full Text] [Related]
5. Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment.
Gmeiner WH
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32575843
[TBL] [Abstract][Full Text] [Related]
6. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
Cao S; Frank C; Rustum YM
J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
[TBL] [Abstract][Full Text] [Related]
7. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
[TBL] [Abstract][Full Text] [Related]
8. Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.
Tao L; Yang JK; Gu Y; Zhou X; Zhao AG; Zheng J; Zhu YJ
World J Gastroenterol; 2015 Jan; 21(4):1125-39. PubMed ID: 25632185
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10.
Gmeiner WH; Miller LD; Chou JW; Dominijanni A; Mutkus L; Marini F; Ruiz J; Dotson T; Thomas KW; Parks G; Bellinger CR
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32224870
[TBL] [Abstract][Full Text] [Related]
10. Therapy for advanced colorectal cancer.
Benson AB
Semin Oncol; 1998 Oct; 25(5 Suppl 11):2-11. PubMed ID: 9786311
[TBL] [Abstract][Full Text] [Related]
11. Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.
Mani C; Pai S; Papke CM; Palle K; Gmeiner WH
Neoplasia; 2018 Dec; 20(12):1236-1245. PubMed ID: 30439567
[TBL] [Abstract][Full Text] [Related]
12. A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.
Rohlff C; Watson SA; Morris TM; Skelton L; Jackman AL; Page MJ
Cancer Res; 1999 Mar; 59(6):1268-72. PubMed ID: 10096558
[TBL] [Abstract][Full Text] [Related]
13. Esculetin enhances the inhibitory effect of 5-Fluorouracil on the proliferation, migration and epithelial-mesenchymal transition of colorectal cancer.
Yan L; Yu HH; Liu YS; Wang YS; Zhao WH
Cancer Biomark; 2019; 24(2):231-240. PubMed ID: 30689555
[TBL] [Abstract][Full Text] [Related]
14. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
Bras-Gonçalves RA; Pocard M; Formento JL; Poirson-Bichat F; De Pinieux G; Pandrea I; Arvelo F; Ronco G; Villa P; Coquelle A; Milano G; Lesuffleur T; Dutrillaux B; Poupon MF
Gastroenterology; 2001 Mar; 120(4):874-88. PubMed ID: 11231942
[TBL] [Abstract][Full Text] [Related]
15. Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway.
Liu H; Liu H; Zhou Z; Parise RA; Chu E; Schmitz JC
Cell Commun Signal; 2018 Feb; 16(1):7. PubMed ID: 29458395
[TBL] [Abstract][Full Text] [Related]
16. Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice.
Chang GR; Kuo CY; Tsai MY; Lin WL; Lin TC; Liao HJ; Chen CH; Wang YC
Molecules; 2021 Aug; 26(15):. PubMed ID: 34361836
[TBL] [Abstract][Full Text] [Related]
17. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors.
Gmeiner WH; Lema-Tome C; Gibo D; Jennings-Gee J; Milligan C; Debinski W
J Neurooncol; 2014 Feb; 116(3):447-54. PubMed ID: 24346635
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.
Fukushima M; Fujioka A; Uchida J; Nakagawa F; Takechi T
Eur J Cancer; 2001 Sep; 37(13):1681-7. PubMed ID: 11527696
[TBL] [Abstract][Full Text] [Related]
20. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
